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Erythrocytic malaria parasites utilize proteases for a number of cellular processes, including hydrolysis of hemoglobin,
rupture of erythrocytes by mature schizonts, and subsequent invasion of erythrocytes by free merozoites. However,
mechanisms used by malaria parasites to control protease activity have not been established. We report here the
identification of an endogenous cysteine protease inhibitor of Plasmodium falciparum, falstatin, based on modest
homology with the Trypanosoma cruzi cysteine protease inhibitor chagasin. Falstatin, expressed in Escherichia coli, was
a potent reversible inhibitor of the P. falciparum cysteine proteases falcipain-2 and falcipain-3, as well as other
parasite- and nonparasite-derived cysteine proteases, but it was a relatively weak inhibitor of the P. falciparum
cysteine proteases falcipain-1 and dipeptidyl aminopeptidase 1. Falstatin is present in schizonts, merozoites, and rings,
but not in trophozoites, the stage at which the cysteine protease activity of P. falciparum is maximal. Falstatin localizes
to the periphery of rings and early schizonts, is diffusely expressed in late schizonts and merozoites, and is released
upon the rupture of mature schizonts. Treatment of late schizionts with antibodies that blocked the inhibitory activity
of falstatin against native and recombinant falcipain-2 and falcipain-3 dose-dependently decreased the subsequent
invasion of erythrocytes by merozoites. These results suggest that P. falciparum requires expression of falstatin to limit
proteolysis by certain host or parasite cysteine proteases during erythrocyte invasion. This mechanism of regulation of
proteolysis suggests new strategies for the development of antimalarial agents that specifically disrupt erythrocyte
invasion.
Citation: Pandey KC, Singh N, Arastu-Kapur S, Bogyo M, Rosenthal PJ (2006) Falstatin, a cysteine protease inhibitor of Plasmodium falciparum, facilitates erythrocyte invasion.
PLoS Pathog 2(11): e117. doi:10.1371/journal.ppat.0020117
Introduction
The genome sequence of Plasmodium falciparum, the most
pathogenic human malaria parasite, predicts over 30 cysteine
proteases [1]. Among these predicted proteases, five have
been biochemically characterized, four falcipains that closely
resemble papain [2–5] and dipeptidyl aminopeptidase 1, an
exopeptidase related to cathepsin C [6]. Numerous additional
sequences predict enzymes related to other families of
cysteine proteases, and it is likely that multiple cysteine
proteases mediate different proteolytic functions during the
complex life cycle of malaria parasites. The best-character-
ized function for plasmodial cysteine proteases is hemoglobin
hydrolysis in erythrocytic trophozoites by falcipain-2 and
falcipain-3 [5]. Inhibition of these proteases [7], disruption of
the falcipain-2 gene [8], or removal of a falcipain-2
hemoglobin-binding domain [9] blocks hemoglobin hydrol-
ysis. Additional processes in erythrocytic parasites that are
mediated by proteases are rupture of erythrocytes by mature
schizonts and subsequent invasion of erythrocytes by free
merozoites. Experiments with protease inhibitors have
yielded somewhat conflicting results, but in most studies
inhibitors of cysteine proteases have inhibited erythrocyte
rupture, and inhibitors of serine (but not cysteine) proteases
have blocked erythrocyte invasion [7,10,11]. The proteases
responsible for erythrocyte rupture are uncertain, although
both the cysteine protease falcipain-2 [12] and the aspartic
protease plasmepsin II [13] have been shown to hydrolyze
erythrocyte cytoskeletal proteins in vitro. Considering eryth-
rocyte invasion, the serine protease PfSUB2 was recently
shown to cleave portions of two merozoite proteins, suggest-
ing that this protease is required for invasion [14]. In non-
erythrocytic parasites, cysteine protease inhibitors blocked
the invasion of hepatocytes by P. falciparum sporozoites,
probably by blocking the proteolytic cleavage of the circum-
sporozoite protein [15], and the disruption of a putative
cysteine protease gene of Plasmodium berghei prevented
sporozoite egress from oocysts [16].
Systems for the control of plasmodial protease activity have
not been described. Endogenous cysteine protease inhibitors
have been described in a number of eukaryotic systems. In
mammalian and plant cells, lysosomal cysteine proteases are
regulated by endogenous polypeptide inhibitors from the
cystatin superfamily [17]. Functional significance is suggested
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by the observation that cystatin C regulates cell surface
expression of MHC class II molecules in dendritic cells [18].
Additionally, in mammalian cells an endogenous inhibitor of
calpain, calpastatin, regulates the activity of calpain [17]. In
protozoan parasites, endogenous protease inhibitors may
both regulate the activity of microbial proteases and prevent
deleterious effects of host enzymes. Endogenous cysteine
protease inhibitors have been described in Trypanosoma cruzi
[19], Leishmania mexicana [20], and Entamoeba histolytica [21]. In
T. cruzi, chagasin is an inhibitor of the cysteine protease
cruzain and other cysteine proteases [19]. Overexpression of
this inhibitor or addition of recombinant chagasin decreased
the infectivity of T. cruzi in cell cultures [22]. In L. mexicana,
disruption of an endogenous cysteine protease inhibitor led
to markedly reduced virulence in mice [20].
We set out to identify an endogenous cysteine protease
inhibitor in P. falciparum. Erythrocytic P. falciparum parasites
express falstatin, a potent inhibitor of falcipains and many
other cysteine proteases. The stage-specificity of falstatin
expression and the effects of anti-falstatin antibodies on
parasite development suggest that, paradoxically, this inhib-
itor facilitates a process that also requires proteolytic activity,
the invasion of erythrocytes by P. falciparum merozoites.
Results
Identification, Expression, and Biochemical
Characterization of Falstatin
We searched for a gene encoding a putative cysteine
protease inhibitor in P. falciparum using the T. cruzi inhibitor
chagasin as a probe in a BLAST search. We identified a P.
falciparum gene (PFI0580c) encoding a predicted inhibitor,
falstatin, with weak homology to chagasin (Figure 1). A
sequence comparison algorithm (Signal IP 3.0) predicted that
falstatin has a typical N-terminal signal sequence. Falstatin is
much larger than chagasin, and amino acid similarities are
limited to small portions of the molecules. The predicted
molecular mass of falstatin is 46.97 kDa. Falstatin is much
more similar in size and sequence to homologous genes from
other plasmodial species (Figure 1).
The falstatin gene was amplified from 3D7 strain P.
falciparum cDNA and inserted into an expression vector, and
falstatin was expressed in Escherichia coli as soluble recombi-
nant protein. Falstatin was purified by nickel-nitrilotriacetic
acid (Ni-NTA) affinity chromatography, based on a His tag
introduced into the recombinant protein, followed by ion
exchange chromatography (Figure 2).
Kinetic studies showed that falstatin is a picomolar inhibitor
of falcipain-2 and falcipain-3, the principal cysteine protease
hemoglobinases of erythrocytic malaria parasites (Table 1).
Falstatin similarly inhibited homologous cysteine proteases
from other plasmodial species (Table 1). However, falstatin did
not inhibit the activity of trophozoite lysates against the
exopeptidase substrate Pro-Arg-AMC, which is an optimal
substrate for P. falciparum dipeptidyl aminopeptidase 1 [6].
Considering proteases from other organisms, falstatin in-
hibited numerous other cysteine proteases, with picomolar
activity against the human cysteine proteases cathepsin K,
cathepsin L, cathepsin H, and calpain-1, and nanomolar
activity against the more distantly related cysteine proteases
caspase 3 and caspase 8 (Table 1). Falstatin did not inhibit two
cysteine proteases with exopeptidase activity, cathepsin B and
cathepsin C. In addition, it did not inhibit proteases of other
catalytic classes, including the serine proteases trypsin and a
chymotrypsin, the aspartic proteases pepsin and renin, and the
metalloproteases collagenase and matrix metalloprotease-2
(Figure 3). In summary, falstatin is a potent inhibitor of many
cysteine proteases, but not other catalytic classes of proteases.
Mechanism of Inhibition by Falstatin
Falstatin was a competitive and reversible inhibitor of
falcipain-2, as demonstrated by increasing calculated Km
values but similar Vmax values with increasing concentrations
of falstatin [23]. Without inhibitor, the calculated Km and
Vmax of falcipain-2, for the substrate benzyloxycarbonyl-Leu-
Arg-7-amino-4-methylcoumarin (Z-Leu-Arg-AMC), were 7.46
lM and 2.513107 lmol/s, respectively. In 12 nM falstatin, the
calculated Km and Vmax were 11.3 lM and 2.203 10
7 lmol/s,
and in 18 nM falstatin these values were 41 lM and 2.02 3
107 lmol/s, respectively.
Typical small molecule cysteine protease inhibitors act by
binding to the protease active site to block enzyme-substrate
interaction [24]. We previously showed that, in contrast, the
prodomain of falcipain-2, which is a picomolar inhibitor of
the enzyme, binds to the catalytic domain of the protease
independent of the active site [25]. To evaluate the
mechanism of inhibition of cysteine proteases by falstatin,
we tested the ability of active site-inhibited falcipain-2 (FP2E-
64) to compete with active falcipain-2 for binding to falstatin.
In contrast to results with the prodomain, the inhibitory
effect of falstatin was not affected by the presence of FP2E-64
(Figure 4). Thus, the binding of falstatin to falcipain-2
appears to be via interaction with the enzyme active site.
Further, kinetic studies showed that D10falcipain-2, an active
enzyme lacking a C-terminal hemoglobin-binding domain [9],
was nearly as well inhibited by falstatin as the wild-type
enzyme, indicating that, unlike the inhibitory prodomain,
falstatin does not require the C-terminal domain for
interaction with falcipain-2 (Table 1).
Stage-Specific Expression and Localization of Falstatin
Polyclonal antisera were raised against falstatin, and
specific antibodies were purified by affinity chromatography
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Synopsis
Malaria causes hundreds of millions of illnesses and more than a
million deaths each year. Illness is caused by infection of red blood
cells, with repeated rounds of red cell invasion, parasite develop-
ment, and red cell rupture. Among enzymes with important roles in
malaria parasites are proteases, which break down other proteins.
Functions of proteases include the breakdown of red cell
hemoglobin, the release of parasites from red cells, and the invasion
of red cells by free parasites. This work concerns the identification
and characterization of a protease inhibitor of malaria parasites
termed falstatin. Falstatin inhibits one class of proteases, cysteine
proteases, from both malaria parasites and humans. It is produced
from soon before until soon after the processes of red cell rupture
and invasion. Incubation of malaria parasites with an antibody that
prevents the effects of falstatin markedly inhibited red cell invasion.
Thus, falstatin appears to facilitate red cell invasion, presumably by
preventing the action of proteases that hinder this process. Falstatin
may therefore be a potential new target for vaccines or drugs to
control malaria.
with Sepharose-coupled falstatin. Extracts from highly
synchronized parasites were then evaluated to characterize
the stage-specific expression of the inhibitor. Immunoblots
demonstrated maximal expression of falstatin in late schiz-
onts and early rings, less expression in late rings and early
schizonts, and no apparent expression in trophozoites (Figure
5). These results are consistent with microarray data, which
showed maximal transcription of the falstatin gene in late
schizonts and early rings [26], and proteomic data, which
identified a single falstatin peptide in only one erythrocytic
stage, merozoites [27].
Anti-falstatin antibodies were also used to characterize the
localization of falstatin by immunofluorescence and immu-
noelectron microscopy. Consistent with immunoblotting
results, falstatin was seen in schizonts, merozoites, and rings,
with apparent maximal expression from the late-schizont to
early-ring stage (Figure 6A). Immunofluorescence images with
3D7 and W2-strain parasites showed very similar results, with
punctate peripheral staining in rings, no staining of
trophozoites, peripheral staining of early schizonts, and
strong diffuse staining of mature schizonts and free mer-
ozoites. Electron microscopy of very mature schizonts
demonstrated diffuse localization of falstatin within mero-
zoites, without clear localization to intracellular organelles or
membranes (Figure 6B). Control cells incubated with the
same concentrations of pre-immune sera and second anti-
body did not show staining by immunofluorescence or
immunoelectron microscopy.
Release of Falstatin with Schizont Lysis
Falstatin contains a typical signal sequence, but the
importance of this sequence for its targeting is uncertain.
To determine if falstatin is released from infected erythro-
cytes, we cultured highly synchronized late schizonts,
collected culture media over 10 h, and assessed for the
Figure 1. Alignment of Falstatin with Chagasin and Putative Cysteine Protease Inhibitors of Other Plasmodial Species
Sequences were aligned using the CLUSTALW program. Amino acid identities with falstatin are in blue, and amino acids of falstatin are numbered. The
predicted N-terminal signal sequence is underlined.
doi:10.1371/journal.ppat.0020117.g001
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presence of falstatin in media by immunoprecipitation with
anti-falstatin antisera followed by immunoblotting. Falstatin
was not detected in media from intact mature schizonts, but
it was detected after schizont rupture (Figure 7). Thus, we did
not identify secretion of falstatin by intact infected eryth-
rocytes, but we did document the release of the inhibitor
upon erythrocyte rupture.
Interaction of Falstatin with P. falciparum Cysteine
Proteases
To better characterize potential targets of falstatin, we
performed competition experiments between falstatin and
the inhibitor DCG04, which has previously been shown to
label falcipain-1, falcipain-2, and falcipain-3 (the latter two
proteins co-migrate on SDS-PAGE gels), and dipeptidyl
aminopeptidase 1 in P. falciparum lysates [6,28]. Competition
experiments with different concentrations of falstatin and
radio-iodinated DCG04 showed that the inhibitor interacts
readily with native falcipain-2 and falcipain-3, but has much
weaker binding to falcipain-1 and dipeptidyl aminopeptidase
1 (Figure 8A). These results suggest that among parasite
proteases, falcipain-2 and falcipain-3 are the principal targets
of falstatin inhibition.
Falstatin Facilitates the Invasion of Erythrocytes by P.
falciparum Merozoites
Adding recombinant falstatin (50 lg/ml) to cultured para-
sites led to no significant changes in rates of rupture or
invasion of erythrocytes as compared to controls (schizont
parasitemia increased from 3.5% 6 1.13% to 4.4% 6 1.06%
after 12 h; ring parasitemia decreased from 6.6% 6 1.0% to
5.9% 6 0.6% after 20 h). Antibodies raised against falstatin
blocked the inhibitory action of this molecule. Inhibition of
falcipain-2, falcipain-3, and the cysteine protease activity of
trophozoite extracts was blocked by purified antibodies in a
dose-dependent fashion (Figure 9). Similarly, the antibodies
blocked competition by falstatin for binding of native
falcipain-2 and falcipain-3 to labeled DCG04 (Figure 8B).
The blocking effects of the antibodies were overcome by
increasing concentrations of falstatin (Figure 8C). The anti-
bodies were thus a valuable tool for studying the biological
role of falstatin. When incubated with erythrocytic parasites
at the ring, trophozoite, or schizont stage, no effects of the
antibodies were seen during the course of a single eryth-
rocytic cycle. This result is not surprising, as antibodies would
not be expected to access intracellular falstatin. It was of
greater interest to assess the impact of anti-falstatin anti-
bodies on the rupture of mature infected erythrocytes or the
subsequent invasion of erythrocytes by merozoites. Purified P.
falciparum schizonts were incubated with uninfected eryth-
rocytes in the presence of the cell permeable cysteine
protease inhibitor (2S, 3S)-trans-epoxysuccinyl-L-leucylami-
do-3 methybutane ethyl ester (E-64d) or antibodies against
falstatin, and persisting schizonts and new rings were counted
after 12 h and 20 h, respectively. Consistent with earlier
reports, E-64d caused a dose-dependent inhibition of
erythrocyte rupture, with accumulation of intact schizonts
and decreased formation of new rings [28,29]. In contrast,
cultures incubated with anti-falstatin antibodies showed no
accumulation of schizonts, but ;80% inhibition in new ring
formation (Figure 10). Thus, for the antibody-treated para-
sites, the lack of new ring formation appeared to be due to a
specific inhibition of merozoite invasion. In a separate
experiment, the effects of multiple concentrations of anti-
bodies were evaluated after a 20-h incubation, beginning at
the schizont stage. Anti-falstatin antibodies blocked eryth-
rocyte invasion in a dose-dependent manner. This effect was
reversed by preincubation of the antibodies with falstatin.
Pre-immune serum and a control immune serum had no
effect on invasion (Figure 10). Thus, falstatin activity is
required for efficient invasion of erythrocytes by merozoites.
Discussion
We have identified and characterized an endogenous
cysteine protease inhibitor of P. falciparum. Falstatin shows
only modest similarity with chagasin, its closest known
relative from another genus, but predicted homologs from
Figure 2. Expression and Purification of Falstatin
Falstatin was expressed in E. coli and purified by Ni-NTA affinity
chromatography and ion exchange (IEX) chromatography. Protein was
resolved by SDS-PAGE and stained with Coomassie blue. The positions of
molecular weight markers (kDa) are indicated.
doi:10.1371/journal.ppat.0020117.g002
Table 1. Inhibition of Cysteine Proteases by Falstatin
Enzyme Ki
a (nM)
Falcipain-2 0.021 6 .008
D10Falcipain-2 0.045 6 .008
Falcipain-29 0.031 6 .006
Falcipain-3 0.223 6 .022
Vivapain-3 0.065 6 .011
Knowlepain-2 0.078 6 .018
Berghepain-2 0.048 6 .009
Vinckepain-2 0.150 6 .033
Papain 53.5 6 19
Cathepsin K 0.025 6 .011
Cathepsin L 0.032 6 .008
Cathepsin H 0.052 6 .014
Cathepsin B No inhibition
Cathepsin C No inhibition
Calpain-1 0.196 6 .058
Caspase 3 376 6 47
Caspase 8 80 6 23
aResults utilizing substrates for each enzyme as detailed in Materials and Methods include
standard deviations from two independent measurements, each performed in duplicate.
doi:10.1371/journal.ppat.0020117.t001
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other plasmodial species have higher levels of identity. As is
the case with cystatins and chagasin, falstatin is a potent
inhibitor of papain-family cysteine proteases, including P.
falciparum falcipains and a number of host cathepsins.
Falstatin is expressed most highly by mature schizonts,
merozoites, and young rings, suggesting roles in erythrocyte
rupture and/or invasion. Indeed, falstatin is released upon
schizont rupture, and antibodies that inhibited falstatin
action specifically blocked merozoite invasion of erythro-
cytes, suggesting that the inhibitor functions to prevent
inappropriate activity by parasite and/or host cysteine
proteases, and thereby facilitates erythrocyte invasion.
Falstatin represents a new family of macromolecular
protease inhibitors. As is the case with cystatins, which bear
no obvious homology, and chagasin, which is distantly related,
falstatin inhibits a wide range of cysteine proteases. Activity
against falcipains, homologs from other plasmodial species,
and the human cysteine proteases cathepsin L, cathepsin H,
cathepsin K, and calpain are all in the picomolar range. Less
potent activity was seen against papain and human caspases.
In contrast to both cystatins and chagasin, however, falstatin
did not inhibit two human cysteine proteases with exopepti-
dase activity, cathepsin B and cathepsin C. Similarly,
dipeptidyl aminopeptidase 1, a P. falciparum cysteine exopep-
tidase, was not inhibited by falstatin. In studies with falcipain-
2, falstatin was seen to be a reversible, active site-binding
inhibitor. Thus, falstatin is well equipped to inhibit parasite
or host cysteine proteases at the times at which it is highly
expressed.
It seems logical that falstatin functions to limit the
activities of parasite and/or host cysteine proteases. Control
of papain-family cysteine protease activity may be warranted,
as this class of enzymes typically exhibits rather non-specific
activity [30]. Indeed, the prototype for this family, papain, is
used in many industrial applications due to its nonspecific
action against protease substrates. Activity against a range of
peptide bonds seems a desired feature of enzymes responsible
for bulk proteolysis, as exemplified by hemoglobin hydrolysis
by plasmodial trophozoites. The principal cysteine protease
hemoglobinases, falcipain-2 and falcipain-3, are expressed by
trophozoites, and hydrolyze hemoglobin in the acidic food
vacuoles of these parasites [2,4,31,32]. Importantly, falstatin
expression is not apparent in trophozoites. Presumably,
control of the action of trophozoite food vacuole cysteine
proteases by a parasite inhibitor is not needed. Cysteine
protease activity is less pronounced in other stages of
Figure 5. Stage-Specific Expression of Falstatin
Extracts from highly synchronized parasites were collected every 8 h,
separated by SDS-PAGE, and evaluated by immunoblotting with anti-
falstatin antibodies. Each sample of early-ring, late-ring, early-tropho-
zoite, late-trophozite, early-schizont, or late-schizont extracts corre-
sponded to 1.33 107 parasitized cells. The positions of molecular weight
markers (kDa) are indicated. ER, early-ring; LR, late-ring; ET, early-
trophozite; LT, late-trophozite; ES, early-schizont; LS, late-schizont.
doi:10.1371/journal.ppat.0020117.g005
Figure 4. Mechanism of Interaction of Falstatin with Falcipain-2
Activity (arbitrary fluorescent units (FU) per minute) against Z-Leu-Arg-
AMC is shown for indicated mixtures of falcipain-2 (FP2) and inactivated
falcipain-2 (FP2E-64) with falstatin. Reaction components were incubated
for 15 min before the addition of substrate and measurement of
fluorescence over time. Error bars represent the standard deviations of
results from two different assays, each performed in duplicate.
doi:10.1371/journal.ppat.0020117.g004
Figure 3. Activity of Falstatin against Different Classes of Proteases
Equal amounts (4 lg) of proteases (FP2, falcipain-2; FP3, falcipain-3;
trypsin; a-chymo, a-chymotrypsin; pepsin; renin; collagenase; MM-2,
matrix-metalloprotease-2) were mixed with 350 ll of appropriate buffers
containing falstatin (1.5 lg) for 15 min, FITC-casein (20 lg) was added,
and hydrolysis of the substrate with and without falstatin was compared
for each protease. Error bars represent the standard deviations of results
from two different assays, each performed in duplicate.
doi:10.1371/journal.ppat.0020117.g003
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erythrocytic parasites, but some expression of this class of
enzymes is seen throughout the erythrocytic cycle [4,8,29,31].
It is likely that cysteine proteases mediate additional parasite
activities. In particular, there is strong evidence for cysteine
proteases participating in erythrocyte rupture by mature
schizonts [10,32,33], although the precise steps blocked by
cysteine protease inhibitors are uncertain [34,35]. Some data
have also suggested a role for falcipains in erythrocyte
invasion by merozoites. Recently, inhibitor studies using a
selective inhibitor implicated falcipain-1 in host-cell invasion
[28]. However, results from other studies using cysteine
protease inhibitors and the generation of viable falcipain-1
knockout parasites [29,36] leave the specific role of this
protease in erythrocyte invasion uncertain.
Studies using small molecule inhibitors have implicated
serine proteases as playing important roles in erythrocyte
invasion [32,37–39]. Proteolytic activities that immediately
precede or accompany erythrocyte invasion include the
ordered processing of some merozoite surface proteins,
including merozoite surface protein-1, followed by the
shedding of remaining merozoite surface proteins, including
merozoite surface protein-1 and apical merozoite antigen-1
Figure 6. Immunolocalization of Falstatin
(A) Immunofluorescence microscopy. Erythrocytes infected with synchronized 3D7 or W2 parasites were collected every 8 h, stained with DAPI and anti-
falstatin antibodies and FITC-second antibody, and then evaluated by immunofluorescence microscopy.
(B) Immunoelectron microscopy. Late-schizont stage parasites were incubated with anti-falstatin antibodies and gold-conjugated second antibody and
then evaluated by electron microscopy. Labels show individual merozoites (M) and erythrocyte cytosol (EC).
doi:10.1371/journal.ppat.0020117.g006
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[39]. Recent work has implicated the P. falciparum subtilisin
homolog pfSUB2 in this critical shedding process, linking
serine proteases to the process of host-cell invasion [14].
Summarizing available data, cysteine proteases play clear
roles in hemoglobin hydrolysis by trophozoites and probably
help to mediate erythrocyte rupture by mature schizonts.
Serine proteases appear to mediate essential steps in
erythrocyte invasion by merozoites. Why, then, is falstatin
produced by late schizonts and merozoites and released into
culture medium upon schizont rupture? We propose that
falstatin functions to limit cysteine protease activity at the
site of parasite invasion to allow selective hydrolysis by other
enzymes and thereby facilitates efficient invasion of eryth-
rocytes. The parasite proteases that are acted upon by
falstatin are most likely falcipains and other cysteine
proteases that have been liberated by schizont rupture and
that, unchecked, could disrupt the limited proteolysis by
serine proteases that is required for erythrocyte invasion.
Although abundant in late schizonts, falstatin apparently
does not prevent activity of cysteine proteases that facilitate
erythrocyte rupture [7,10,11], presumably due to different
intracellular locations of active proteases and the inhibitor.
In any event, our data strongly suggest that expression of
falstatin is required for efficient invasion of erythrocytes by
free merozoites.
Inhibition of host proteases by falstatin may also be
biologically relevant. Lysosomal cysteine proteases, including
cathepsin L and a number of related enzymes, have uncertain
roles in erythrocytes, but proteases released by macrophages
or other cells might act, via nonspecific proteolysis, to
prevent erythrocyte invasion by free merozoites. Falstatin
also inhibits human calpain-1, a related papain-family
protease. Calpain-1 is localized to the inner surface of the
erythrocyte cytoskeleton [40], and it is possible that inhibition
of this host intracellular protease activity is required for
efficient parasite development.
Our identification of falstatin and demonstration of its
likely role in erythrocyte invasion by merozoites offers
potential new approaches for the control of malaria. As
demonstrated by our studies with specific antibodies, com-
pounds that block falstatin function inhibit parasite develop-
ment. Both drugs directed against falstatin or vaccines that
elicit antibodies that block its action might offer new means,
ideally in concert with other approaches, of controlling
malaria. In addition, other proteases and protease inhibitors
probably play key roles in the life cycle of malaria parasites,
and additional research to elucidate the functions of these
proteins is warranted.
Materials and Methods
Expression and purification of recombinant falstatin. The falstatin
gene was identified by a BLAST search using the chagasin sequence.
The falstatin gene was amplified from 3D7 strain P. falciparum cDNA
using forward (59-GATGGATCCAATAACAGCTACTCATTT-
GAAATTGTG-39) and reverse (59-CGGAAGCTTATTGCACGTT-
TAACTCTACAATTCT-39) primers spanning the predicted open
reading frame. The PCR product was digested with BamHI and
HindIII, gel purified, and ligated into an appropriately digested pQE-
30 plasmid (Qiagen, Valencia, California, United States), which
encodes an amino terminal 6-His tag, to produce expression
construct pQ-fal. This construct was used to transform the M15
(pREP4) strain of E. coli, and bacteria containing pQ-fal were grown to
mid-log phase and then induced with 0.5 mM isopropyl-1-thio-b-D-
galactopyranoside for 3 h at 33 8C. Cells were harvested, washed with
ice-cold 10 mM Tris (pH 8.0), sonicated (five cycles of 5 s each, with
cooling for 30 s between the cycles), and centrifuged at 12,0003 g for
30 min at 4 8C. For purification of the recombinant protein, the
supernatant was incubated overnight at 4 8C with Ni-NTA resin
(Qiagen) equilibrated with 10 mM Tris (pH 8.0). The column was
washed with ten bed volumes of the same buffer and 50 mM
imidazole, and bound protein was eluted with a continuous gradient
(50 mM–1 M) of imidazole. The Ni-NTA purified protein was bound
to a Q-Sepharose (Amersham Biosciences, Little Chalfont, United
Kingdom) column in 10 mM Tris (pH 8.0). The column was washed
with five column volumes of 100 mM NaCl in the same buffer and
bound protein was eluted with a continuous salt gradient (100 mM–1
M NaCl). Purified protein was analyzed with SDS PAGE and the
Bradford dye assay. The sequences of recombinant genes in
expression constructs were confirmed by DNA sequencing.
Inhibitor kinetics. The cysteine proteases falcipain-2 [2], falcipain-
29 [3], D10falcipain-2 [9], falcipain-3 [4], vivapain-3 [41], knowlepain-2
[25], berghepain-2 [42], and vinckepain-2 [42] were produced as
described earlier. Cathepsins K, L, H, B, and C and papain were from
Sigma (St. Louis, Missouri, United States), and calpain-1, caspase-3,
and caspase-8 were from Calbiochem (San Diego, California, United
States). Inhibitor kinetics were calculated as previously described [9].
Briefly, the concentrations of these enzymes (2–10 nM for all assays)
were determined by active site titration with morpholine urea–
leucine–homophenylalanine-fluoromethyl ketone (Mu-Leu-Hph-
FMK; Peptides International; plasmodial enzymes), N-(trans-epoxy-
succinyl-L-leucine 4-guanidinobutylamide (E-64; Sigma; cathepsin B,
K, L, and H), acetyl–Asp-Glu-Val-Asp-chloro methyl ketone, (Ac-
DEVD-CMK; Calbiochem; caspases), and chicken cystatin (Sigma;
cathepsin C). Proteolytic substrates (5–20 lM; ;2-fold below Km)
were Z-Leu-Arg-AMC (Peptides International; plasmodial proteases),
Z-Phe-Arg-AMC (Peptides International; cathepsins K, L, and H and
papain), Z-Arg-Arg-AMC (Peptides International; cathepsin B), Pro-
Arg-AMC (Bachem; dipeptidyl aminopeptidases), H-Lys(FAM)–Glu-
Val-Tyr-Gly-Met-Met-Lys(Dabcyl)-OH (Calbiochem; calpain-1 [43]),
Gly-Phe-4 methoxy-b-napthylamide (Bachem; cathepsin C [44]),
acetyl-Ile-Glu-Thr-Asp-paranitroaniline (Ac-IETD-pNA; Calbiochem;
caspase-8), and acetyl-Asp-Glu-Val-Asp-7 amino-4 methylcoumarin
(Ac-DEVD-AMC; Calbiochem; caspase-3). Assay buffers were 100 mM
acetate buffer, 8 mM dithiothreitol (DTT) (pH 5.5) (plasmodial
proteases); 100 mM acetate buffer, 1 mM ethylene diamine
tetraactetic acid (EDTA), 400 mM NaCl, 10% glycerol (pH 5.5)
(cathepsins); 50 mM N-(2-hydroxyethyl)-piperazine-N9-2-ethanesul-
Figure 7. Release of Falstatin with Schizont Lysis
Synchronized late-schizont-infected erythrocytes were cultured in Albu-
max-free medium. At the indicated time points culture media were
collected and concentrated, falstatin was immunoprecipitated with anti-
falstatin antiserum and anti-rat IgG beads, the beads were washed, bound
proteins were solubilized in sample buffer, and falstatin was resolved by
SDS-PAGE and identified by immunoblotting. Controls with pre-immune
serum did not immunoprecipitate any detectable proteins. The positions
of molecular weight markers are indicated (kDa). Schizont and ring
parasitemias at the indicated time points are shown below the gel.
doi:10.1371/journal.ppat.0020117.g007
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fonic acid (HEPES), 100 mM NaCl, 10 mM DTT, 1 mM EDTA, 10%
glycerol, 0.1% 3-f(3-cholamidopropyl) dimethylammoniog-1-propane
sulfonate (CHAPS) (pH 7.4) (caspases), and 20 mM imidazole, 5 mM b-
mercaptoethanol, 5 mM CaCl2, 1 mM EDTA, 1 mM ethylene glycol-bis
(b-aminoethyl ether)-N,N,N9N9-tetraacetic acid (EGTA), 30% glycerol
(pH 6.8) (calpain-1). To assay the inhibitory activity of falstatin against
P. falciparum dipeptidyl peptidases, saponin-treated trophozoites (7.8
3105 parasites per reaction) were incubated with and without falstatin
(50 lg/350 ll), and activity against the substrate Pro-Arg-AMC was
assessed as previously described [6].
For kinetic assays, different concentrations of falstatin were
incubated with enzymes for 10 min at room temperature. The lowest
inhibitor concentration studied was at least ten times the enzyme
concentration to ensure pseudo-first-order reaction conditions [45].
Substrates were then added, product formation was continuously
measured for 20 min at room temperature with a spectrofluorometer,
and Ki values were determined by nonlinear regression analysis using
PRISM (GraphPad Software, San Diego, California, United States).
Activities of falcipains (in buffers as described above) and
proteases from other catalytic classes (all from Sigma) were compared
as hydrolysis of FITC-casein in the following buffers: 100 mM
phosphate (pH 7.6) (trypsin), 50 mM Tris (pH 7.8) (a-chymotrypsin),
100 mM acetate (pH 4.0) (pepsin), 100 mM phosphate (pH 6.0) (renin),
50 mM Tris (pH 7.5) (collagenase), and 100 mM phosphate, 150 mM
NaCl, 0.025% Brij-35, 50% glycerol (pH 7.4) (matrix-metalloprotease-
2). Enzymes (4 lg) were incubated in 350-ll reactions with falstatin
(1.5 lg) at room temperature for 15 min. FITC-casein (20 lg) was
added, and fluorescence resulting from hydrolysis was measured
(excitation 485 nm, emission 527 nm) continuously over 10 min.
To assess the mechanism of inhibition of falcipain-2, varied
amounts (0.5–2.0 lg) of inactive falcipain-2 (FP2E-64), prepared as
described previously [9], and constant amounts of active falcipain-2
(0.5 lg), and falstatin (1 lg) were mixed in 350-ll assay buffer for 15
min at room temperature. Hydrolysis of the substrate Z-Leu-Arg-
AMC by the protease was studied as described above.
Anti-falstatin antibodies. Rats were immunized by the intra-
peritoneal route with 100 lg of recombinant purified falstatin
emulsified in complete Freund’s adjuvant. The rats were boosted on
Figure 8. Inhibitor Competition
The indicated amounts of falstatin and anti-falstatin antibody were incubated with lysates from asynchronous parasite cultures before addition of [125I]
DCG04, electrophoresis, and analysis by autoradiography. Results with increasing concentrations of falstatin (A), increasing concentrations of antibody
(B), and increasing falstatin in the presence of antibody (C) are shown. Labels above the gels represent concentrations of falstatin and antibody (lg/ml).
Proteins are labeled based on known migration patterns that were previously confirmed by mass spectrometry. FP, falcipain; DPAP1, dipeptidyl
aminopeptidase1[28].
doi:10.1371/journal.ppat.0020117.g008
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Figure 9. Inhibition of Falstatin Function by Anti-Falstatin Antibodies
Hydrolysis of the peptide substrate Z-Leu-Arg-AMC by falcipain-2 (FP2; 19.8 nM), falcipain-3 (FP3; 27.1 nM), or trophozoite extract (TE; corresponding to
5.53106 parasites per reaction) was evaluated in the absence or presence of falstatin (31 nM) and the indicated quantities of anti-falstatin antibodies in
350 ll of 100 mM sodium acetate, 8 mM DTT (pH 6.0). Reaction components were incubated for 15 min before addition of substrate, and activity was
measured as arbitrary fluorescence units over time (FU/min). Error bars represent the standard deviations of results from two different assays, each
performed in duplicate.
doi:10.1371/journal.ppat.0020117.g009
Figure 10. Effect of Anti-Falstatin Antibodies on Cultured Parasites
Schizont-infected erythrocytes were combined with fresh erythrocytes in culture medium with 0.5% DMSO or PBS, pre-immune serum, or the indicated
concentration of E-64d (in DMSO) or antibody (in PBS). Smears were then made and stained with Giemsa, and percentages of schizonts after 12 h (A),
rings after 20 h (B), and total parasites (C) were counted. In a separate experiment (D), purified schizonts were incubated for 20 h with PBS, control pre-
immune serum (50 lg/ml), rat antiserum against P. falciparum farnesyl pyrophosphate synthetase (control Ab; 50 lg/ml), or the indicated
concentrations of antibodies (Ab; lg/ml) in PBS with or without preincubation for 10 min with 2 lg falstatin (F). Errors bars indicate standard deviations
from means of two different assays, each done in triplicate. PI, pre-immune serum.
doi:10.1371/journal.ppat.0020117.g010
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days 33, 66, and 95 with 60 lg of falstatin in incomplete Freund’s
adjuvant. Sera were collected 12–14 d after each immunization and
used for immunoassays. Initial experiments were performed with
immune antisera, but all reported results were with affinity purified
anti-falstatin antibodies. To affinity purify these antibodies, an
affinity column was prepared as described earlier [2]. Briefly,
recombinant antigens (10 mg) were equilibrated with 100 mM sodium
carbonate (pH 8.0), crosslinked to 5 ml of cyanogen bromide-
activated Sepharose Fast Flow (Amersham Bioscience), and pre-
equilibrated with the same buffer overnight at 4 8C. The column was
washed with ten column volumes of 100 mM sodium carbonate (pH
8.0) and blocked with 100 mM Tris (pH 8.0), followed by 1 M
ethanolamine (pH 8.0). The beads were washed again with 0.1 % BSA
in PBS. Diluted antiserum (50 ml, 1:10 in PBS, 0.1% BSA) was then
loaded onto the falstatin-Sepharose Fast Flow column. The column
was washed with 100 ml each of PBS with 500 mM NaCl, 10 mM
phosphate (pH 6.8), and 150 mM NaCl. Purified antibodies were
eluted with 100 mM glycine, 150 mM NaCl (pH 2.6), collected in 2 ml
fractions containing 200 ll of 1M Tris (pH 8.0), run through 0.4-lm
filters, and stored at 20 8C. For immunofluorescence studies,
antibodies (1 mg/ml) were further pre-absorbed with acetone-treated
erythrocytes as follows: Human erythrocytes (500-ll packed cells)
were treated with 10 ml of chilled acetone for 30 min at room
temperature and then washed six times with PBS. Antibodies were
incubated with treated cells for 40 min at 4 8C, cells were centrifuged
at 15,300 3 g, and the supernatant was used for immunofloresence
assays.
To assess the functional activity of antibodies against falstatin,
recombinant falcipain-2 (19.8 nM), falcipain-3 (27.1 nM), or troph-
ozoite extracts (corresponding to 5.5 3 106 parasites per reaction)
were incubated with falstatin (31 nM) and varied amounts (0.5–1.0 lg)
of antibody in 350-ll assay buffer (100 mM sodium acetate [pH 6.0], 8
mM DTT) before addition of Z-Leu-Arg-AMC and measurement of
hydrolysis, as described above.
Parasite culture and immunoblotting. P. falciparum strains 3D7 and
W2 were cultured using standard methods in human erythrocytes at
2% hematocrit in RPMI 1640 medium supplemented with 25 mM
Hepes, 30 mg/liter hypoxanthine, 0.225% NaHCO3, and 0.5 %
Albumax (Life Technologies, Carlsbad, California, United States).
Synchronization was maintained by serial treatment with 5% D-
sorbitol [46]. Erythrocytes infected with highly synchronous late
schizonts were enriched by flotation on 63% Percoll (Sigma). The
interphase containing schizont-infected erythrocytes was collected
and washed twice with RPMI media. For immunoblots, infected
erythrocytes were washed with ice-cold PBS, lysed with 0.1% saponin
in ice-cold PBS for 10 min, centrifuged (2,0603 g for 10 min at 4 8C),
washed three times with ice-cold PBS, and stored at70 8C. Samples
corresponding to 1.3 3 107 parasitized cells per lane were then
incubated with SDS PAGE buffer, boiled for 10 min, and centrifuged
at 15,3003 g at 4 8C for 20 min; soluble proteins were separated by
10% SDS PAGE and transferred to a nitrocellose membrane. The
membranes were blocked with 1.5% BSA and 1% fat-free milk in PBS
overnight at 4 8C and incubated with affinity purified anti-falstatin
antibody (10 lg/ml) in PBS with 0.5% BSA and 0.5% fat-free milk for
1 h at room temperature. The membranes were washed and
incubated with alkaline phosphatase-conjugated goat anti-rat IgG
(1:8,000; Jackson Immuno Research, West Grove, Pennsylvania,
United States) in the same solution at room temperature for 1 h.
After incubation, membranes were extensively washed with PBS
containing 0.2% Tween-20, and antigen–antibody complexes were
developed using 5-bromo-4-chloro-3–indolyl phosphate/nitroblue
tetrazolium tablets (Sigma) following manufacturer’s instructions.
Immunofluorescence microscopy. Erythrocytes infected with
synchronized parasites were washed twice in PBS and allowed to
attach to poly-L-lysine coated slides (Electron Microscopy Science)
for 1 h at room temperature. Cells were then fixed with 4% EM grade
paraformaldehyde (Sigma) in PBS for 30 min, treated with 0.1%
Triton-X 100 in PBS for 30 min, rinsed with PBS, and blocked with
blocking buffer (1% BSA in PBS) for 1 h at room temperature in a
humidified chamber. Anti-falstatin antibodies (affinity-purified and
pre-absorbed with red blood cells, as described above; 30 lg/ml) and
pre-immune rat sera (1:100) were diluted in blocking buffer and
incubated with the fixed and blocked cells overnight in a humidified
chamber. Cells were washed four times with PBS, stained with 49-6-
diamidino-2-phenylindole (DAPI) nuclear stain (2 lg/ml) and FITC-
labeled goat anti-rat antibody (1: 500, Sigma), and incubated for 30
min in a humidified chamber. Stained slides were rinsed several times
in PBS, dried, and overlaid with mounting solution (10% mowiol 4–
88, 25% glycerol, 2.5% 1,4 –diazobicyclo-[(2.2.2]–octane, 0.1M Tris
[pH 8.5])[47] and a cover slip before examination by fluorescence
microscopy.
Immunoelectron microscopy. Erythrocytes infected with mature
schizonts were washed three times with PBS and fixed at room
temperature in 1% paraformaldehyde and 0.2% glutaraldehyde in 50
mM phosphate buffer (pH 7.4) for 2 h. Fixed cells were washed,
resuspended in PBS, and kept at 4 8C until analysis by electron
microscopy at the University of California, San Francisco Cell
Imaging Core Facility using standard protocols [48]. Briefly, fixed
samples were cryoprotected with 20% polyvinylpyrrolidone in 2.3 M
sucrose overnight, and frozen in liquid nitrogen. Frozen thin sections
were cut with a Leica Ultracut UCT microtome with EM FCS (Leica
Microsystems, Wetzlar, Germany). Sections were treated with 0.2%
glycine, blocked with 2% fish gelatin, 2% BSA in PBS (pH 7.4), and
then incubated with purified anti-falstatin antibody (50 lg/ml in PBS)
followed by 10 nm colloidal gold (Ted Pella, Incorporated, Redding,
California, United States) conjugated with goat anti-rat IgG (1:50 in
PBS) for 30 min. Sections were stained with oxalate uranyl acetate
and embedded in 1.5% methyl cellulose, 0.3% aqueous uranyl acetate
(Ted Pella), and examined with a Philips Tecnai 10 electron
microscope.
Identification of falstatin in culture supernatants. Late-schizont-
infected erythrocytes (650 ll; 7.63 106 parasites/ll) were prepared as
described above, washed with culture medium lacking Albumax,
gently resuspended in 150 ml (10 ml for the first time point) of
Albumax-free medium, divided into separate flasks, and maintained
at 37 8C until medium was collected. At indicated time points
parasites were examined by evaluation of Giemsa-stained smears, and
the medium was concentrated to 2 ml with an Amicon filter (10-kDa
cut-off; Millipore, Billerica, Massachusetts, United States). Falstatin
was then immunoprecipitated as follows: Concentrated culture
supernatants were incubated with 10 ll anti-falstatin antibody (2
mg/ml) and 13Protease Inhibitor Cocktail Set III (Calbiochem) for 30
min at 4 8C, anti-rat IgG-agarose beads (60 ll of a 50:50 slurry in
Albumax-free medium) were added, reaction mixtures were incu-
bated for 1 h at 4 8C with gentle shaking, and samples were
centrifuged for 10 min at 15,3003 g, 4 8C and washed twice with 50
mM Tris (pH 7.4), 300 mM NaCl, 0.1 % Triton–X 100. Washed beads
were resuspended in 25-ll reducing SDS-PAGE sample buffer, boiled
for 10 min, centrifuged at 15,3003 g, and samples were analyzed by
immunoblotting with anti-falstatin antibodies as described above.
Inhibitor competition experiments. DCG04 was radioiodinated as
described earlier [28]. Asynchronous 3D7 parasites were lysed in 1%
NP-40, and soluble and insoluble fractions were mixed. Approx-
imately 100 lg of total protein, estimated with Bradford reagent, was
used in each reaction. Indicated amounts of falstatin with or without
antibody were incubated with the lysates for 30 min. [I125]DCG04 was
then added and the reactions were continued for 1 hour at room
temperature before adding SDS loading buffer and boiling. Approx-
imately 20 lg of labeled lysate was loaded in each gel lane, samples
were resolved by SDS-PAGE, and gels were analyzed by auto-
radiography.
Rupture and invasion assays. Infected erythrocytes (2% para-
sitemia) at different parasite stages were incubated with anti-falstatin
antibodies or PBS, and morphologies were evaluated over the course
of the life cycle. For studies of effects of antibodies on erythrocyte
rupture and invasion, schizont-infected erythrocytes were purified as
described above and diluted with uninfected erythrocytes to a final
parasitemia of 5%. Infected erythrocytes were then incubated with or
without E-64d (in 0.5% DMSO) or antibody against falstatin (in PBS)
for the indicated intervals, and parasite counts were performed by
microscopic analysis of Giemsa-stained smears (parasites per 500
erythrocytes). Controls were parasites incubated with PBS, 0.5%
DMSO, rat pre-immune sera, and rat antiserum against P. falciparum
farnesyl pyrophosphate synthetase (a gift from A. Lau).
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